DENALI THERAPEUTICS INC
NASDAQ: DNLI (Denali Therapeutics Inc.)
Last update: 7 hours ago17.48
0.11 (0.63%)
| Previous Close | 17.37 |
| Open | 17.25 |
| Volume | 863,493 |
| Avg. Volume (3M) | 1,876,360 |
| Market Cap | 2,563,649,024 |
| Price / Sales | 3.64 |
| Price / Book | 2.76 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -2.64 |
| Total Debt/Equity (MRQ) | 4.59% |
| Current Ratio (MRQ) | 9.56 |
| Operating Cash Flow (TTM) | -365.54 M |
| Levered Free Cash Flow (TTM) | -257.54 M |
| Return on Assets (TTM) | -22.58% |
| Return on Equity (TTM) | -35.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Denali Therapeutics Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.30 |
|
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.86% |
| % Held by Institutions | 94.15% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Temasek Holdings (Private) Ltd | 30 Sep 2025 | 5,355,832 |
| Crestline Management, Lp | 30 Sep 2025 | 3,410,732 |
| 52 Weeks Range | ||
| Median | 26.00 (48.74%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 04 Nov 2025 | 26.00 (48.74%) | Buy | 14.92 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Nov 2025 | Announcement | Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights |
| 06 Nov 2025 | Announcement | Denali Therapeutics Announces Board and Executive Leadership Updates |
| 13 Oct 2025 | Announcement | Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |